Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma
Open Access
Abstract
Synovial sarcoma (SyS) is a rare aggressive soft tissue sarcoma carrying the chromosomal translocation t(X;18), encoding the fusion transcript SS18::SSX. The fusion oncoprotein interacts with both BAF enhancer complexes and polycomb repressor complexes, resulting in genome-wide epigenetic perturbations and a unique altered genetic signature. Over 80% of the patients are initially diagnosed with localized disease and have a 5-year survival rate of 70–80%, but metastatic relapse occurs in 50% of the cases. Advanced, unresectable, or metastatic disease has a 5-year survival rate below 10%, representing a critical issue. This review summarizes the molecular mechanisms behind SyS and illustrates current treatments in front line, second line, and beyond settings. We analyze the use of immune check point inhibitors (ICI) in SyS that do not behave as an ICI-sensitive tumor, claiming the need for predictive genetic signatures and tumor immune microenvironment biomarkers. We highlight the clinical translation of innovative technologies, such as proteolysis targeting chimera (PROTAC) protein degraders or adoptive transfer of engineered immune cells. Adoptive cell transfer of engineered T-cell receptor cells targeting selected cancer/testis antigens has shown promising results against metastatic SyS in early clinical trials and further improvements are awaited from refinements involving immune cell engineering and tumor immune microenvironment enhancement.Keywords
Funding Information
- Italian Ministry of Health
This publication has 81 references indexed in Scilit:
- Synovial Sarcoma (SS)2014
- Identification of target genes of synovial sarcoma-associated fusion oncoprotein using human pluripotent stem cellsBiochemical and Biophysical Research Communications, 2013
- A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial SarcomaSarcoma, 2013
- A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomasEuropean Journal of Cancer, 2012
- Deconstruction of the SS18-SSX Fusion Oncoprotein Complex: Insights into Disease Etiology and TherapeuticsCancer Cell, 2012
- Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in SarcomagenesisClinical Cancer Research, 2011
- Mutational analysis of E-cadherin, β-catenin and APC genes in synovial sarcomasHistopathology, 2010
- Synovial Sarcoma Is a Stem Cell MalignancyStem Cells, 2010
- Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic StudyJournal of Clinical Oncology, 2005
- Histologic Grade, But Not SYT-SSX Fusion Type, Is an Important Prognostic Factor in Patients With Synovial Sarcoma: A Multicenter, Retrospective AnalysisJournal of Clinical Oncology, 2004